BEGIN TO REPORT TO THE MAFIA PHARMACEUTICAL

REPUTED British doctors BEGIN TO REPORT TO THE MAFIA PHARMACEUTICAL Several British doctors, including that outside personal doctor of Queen Elizabeth II, have initiated a debate on the effectiveness of medicines and question the influence of pharmaceutical companies on product consumption whose effectiveness is unproven. Richard Thompson, president of the Royal College of Physicians and personal doctor of queen Elizabeth II for 21 years, has called for an urgent public consultation on "the effectiveness of drugs" is made ​​and the disclosure of handlings "shady" companies in the sector and warned about the excessive influence they have when prescribing drugs. people who lash out against pharmaceutical ensure that many drugs cause more harm than good, while the supposed benefits of some drugs are not properly that have been met . And the pharmaceutical business moves millions of dollars worldwide. At the same time, the excesses of medication and consumption of multiple drugs whose effectiveness is in doubt are some of the factors that cause the death of thousands of people. In this regard it should be noted what it tells us an Argentine doctor in Article COMMENTARY DEVELOPER a DOCTOR oN pERVERSION of modern medicine Among physicians who are driving the debate about excessive power wielded by pharmaceutical on medical activity, the cardiologist Aseem Malhotra, who has accused pharmaceutical companies of "playing with is system ", investing twice as much on marketing than on research. Dr. Malhotra maintains that prescription drugs often do more harm than good, and that the elderly are the group at greatest risk because of these practices so widespread. " one in three hospital admissions among people over 75 years in the UK, are a result of an adverse reaction to a drug , " Dr. Malhotra, who is launching the campaign to denounce his personal capacity, is administrator Think Tank field health King's Fund, a member of the Academy of Medical Royal and advisor to the National Obesity Forum UK Schools.Malhotra is receiving the backing of Sir Richard Thompson, and professor John Ashton, president of the Faculty of health public; psychiatrist Dr. JS Bamrah, president of the British Association of Physicians of Indian Origin;Rita Redberg cardiologist, editor of the medical journal Archives of Internal Medicine; and Professor James McCormack, a pharmaceutical scientist. Malhotra points directly to the British public health because it believes that sobremedica their patients and the resulting side effects caused by this course of action lead to "many deaths". In addition, this cardiologist indicates that there is a suspicion that this "excess medicine" resulting from "financial incentives" related to the prescription and increasing procedures, which accuses the pharmaceutical of "gaming the system" and to invest twice propaganda than research. Malhotra is particularly critical of the recent dramatic increase in prescribing statins and states that the complete data about the power of statins and side effects have not been published. in pharmacology, known as statins , a group of drugs used to lower cholesterol in different forms, in patients who have high (hypercholesterolemia) and which have therefore increased risk of developing atherosclerosis and suffer episodes of cardiovascular disease. bottle-statin in fact, more and more evidence suggests that the benefits of statins have been greatly exaggerated and that their side effects have been widely underestimated. in recent weeks, two independent research groups in Japan and France, independently of one another, have questioned the reliability of many previous studies sponsored by the pharmaceutical industry, which showed the supposed benefits of statins. in fact, the Japanese research went so far as to suggest that statins may be one of the causes of the growing number of affected among the population, heart failure. Meanwhile, the renowned French cardiologist Dr. Michel De Lorgeril says that all studies published after 2006 do not reveal 'no benefit' of statins for prevention of cardiovascular disease in all groups of patients.Among other various research on the damage caused by certain drugs, Malhotra cites research by the medical journal British medical journal, which earlier this month suggests that the main anticoagulant drug rivaroxaban is not as safe as suggested by data from trials, although the regulator continues to support the commercialization of medicine. it also alleges that occurs "biased research funding, aimed at promoting those products that are more profitable, and not those that are most beneficial to patients through information biased in medical journals" "De Indeed, as John Ioannidis, professor of medicine and health policy at Stanford University said: 'as higher are the financial interests at a given, the less likely field is that research results are true' " " all this leads to conflicts of interest of a commercial nature and a clear inability of doctors and patients in understanding health statistics and risk of pharmaceutical products " " all this is contributing to an epidemic of doctors and patients misinformed in the UK and everywhere " " But most worrying of all is that this desperate situation is costing tens of thousands of lives worldwide " " in addition, the problem with polypharmacy (taking more than one drug to time), is that as more drugs are taken, the more likely the patient experiencing side effects which are then misinterpreted by a doctor or nurse as a symptom of illness that needs treatment with additional medications " a few months ago, the medical director NHS (National Health Service in England), Sir Bruce Keogh, admitted that one of every seven NHS treatments, including operations, were unnecessary and should not have been carried out in patients. and in the US, an estimated one third of all activities of health care no benefit to patients. This is further supported by an observation made ​​by the former editor of the New England journal of Medicine, Dr. Marcia Angell. in a lecture at the University of Montana, in 2009, he revealed that of the 667 new drugs approved by the FDA between 2000 and 2007, only 11% were considered innovative or were an improvement of some existing drugs. However, three quarters were essentially only copies of old drugs, which were remarketed to earn even more money with them. "Given the fact that the primary responsibility of pharmaceutical companies to provide benefits to shareholders, rather than worrying about the health of patient, that should not surprise anyone , "says Dr. Malhotra. But apart from the colossal waste that results from financial companies come to market the same drug twice, and therefore marketing spend twice that investing research and development, the worst is considerable damage on patients and the public. the Administration Food and drug Administration (FDA) reports that the adverse effects of prescribed drugs have more than tripled in the last decade in the United States, which has resulted in more than 123,000 deaths in 2014 and 800,000 outcomes of patients suffering severe effects, including hospitalizations and disabilities that threaten their lives ... although many experts say that these data understate the truth, which is much worse. One of experts leading long denounced the dangers of modern medicine is Peter Gotzsche, professor of design and analysis of research at the University of Copenhagen.Gotzsche estimated that prescription drugs are the third most common cause of death after illness heart diseaseand cancer. in particular, it is deeply concerned about the impact of psychiatric drugs such as antidepressants and drugs against dementia. Writing in the British Medical journal, it has calculated that account for more than half a million deaths in the people over 65 years in the European Union and the United States. in fact, because of these attitudes and unclear dealings between 2007 and 2012 almost all pharmaceutical companies that are among the top 10 in the world paid substantial fines for offenses and misrepresentation of research results, concealment of information about the harms of their products and the illegal marketing of drugs. and so they begin to report medical reputed in countries like the UK, where they begin to reveal that the current medical system is completely controlled by the interests of the pharmaceutical industry. However, there are still lots of people who refuse to see this evidence and in many countries, such as Spain, doctors hardly dare to denounce the criminal practices of the pharmaceutical industry , who have hijacked completely the practice of medicine, corrupting and perverting to turn it into a mere business, infinitely more concerned about winning huge amounts of money, which worry about the health of pacient.

information: http://www.dailymail.co.uk/health/article-3460321/How-Big-Pharma-greed-killing-tens-thousands-world-Patients-medicated-given-profitable-drugs-little-proven-benefits-leading-doctors-warn.html
https://actualidad.rt.com/actualidad/200446-negocio-farmaceutico-muerte-miles-pacientes

Politicians and politics

Politicians and politics
Truly, that tenemos Political dan size?
La respuesta is not
* There elitist politicians who dedican criminalizar según to the color of the skin or raza. Donald Tramp is against Immigration
* Quese defican existing politicians to plunder the village enriquecerse para ellos. Mariano Rajoy, and Henry Kisinguer are a ejemplo
* Another class of politicians who are the liars como por ejemplo nature todos los politicos who Tienen on your carteras charge of the economy and Tributos

  votes sensibly to this peaple governament do not know?

La delicada situación de la Sanidad en Catalunya

información facilitada por

kaosenlared.net  


El nuevo conseller de Salut, Toni Comín, se escuda en que la situación se debe a la falta de presupuesto, que no llega para cumplir con el plan de choque prometido por Junts pel Si. Situación, dice Comín, que solo se puede revertir “con la independencia” de Cataluña. “Cualquier persona comprometida con los derechos sociales debería mirar con mucho interés el escenario de la independencia”, ha dicho, porque permitiría que Cataluña pudiera dar respuesta a los problemas de los ciudadanos.
Servicios de Urgencias colapsados, salas de espera llenas, ventanas remendadas, pacientes alojados en pasillos e incluso lavabos sin jabón ni papel higiénico.
Cada día, nuestra publicación hermana Catalunya Press recibe imágenes y quejas de usuarios y profesionales de la Sanidad catalana.
La Marea Blanca de Catalunya denuncia la situación de “emergencia sanitaria” que vive la sanidad catalana consecuencia de los recortes. Una emergencia que se refleja en elcolapso de los servicios de urgencias de los hospitales de toda Cataluña.
Una de las situaciones más graves es la que se vive en el hospital Parc Taulí de Sabadell (Barcelona), en especial su servicio de Urgencias. Tanto trabajadores como usuarios hace tiempo que denuncian su situación de colapso, con “largas horas de espera” que los pacientes padecen.
Además, hay enfermos que pasan días en los pasillos o en boxes por falta de camas.
Asociaciones como la Plataforma Asamblearia de Trabajadoras y Trabajadores (Patt) o la Federación de Asociaciones Vecinales de Sabadell recuerdan que “la falta de recursos puede provocar situaciones de riesgo para las personas”.
Las causas de esta situación: el cierre de plantas y camas, consecuencia de los recortes en recursos económicos y humanos, las externalizaciones y las privatizaciones. El comité de empresa de este hospital califica la situación del centro de “infrahumana”.
Catalunya Press también se ha hecho eco de la situación en LLeida. Los servicios de Urgencias de la comarca de la Noguera están saturados. La Confederación General del Trabajo (CGT) denuncia que de los cinco equipos de enfermeros y médicos que existían en la comarca, ahora hay solo dos. Unos recortes que no solo afectan a la calidad de la atención sino también a los propios profesionales, que se ven desbordados.
Otra situación sangrante es el de los Centro de Atención Primaria (CAP). En el caso de los de Lleida, sus lavabos públicos no tienen papel higiénico ni jabón de manos.
En el reportaje de la televisión Dponent se puede ver que algunos centro han estado más de un día entero sin papel. Los dispensadores de jabón están vacíos en pleno período gripal, cuando hay que extremar la higiene para prevenir contagios. Además, en las piletas se ven resto de sangre.
Una situación que se arrastra hace años en toda Cataluña. En el primer año del anterior conseller de Salut de la Generalitat, Boí Ruiz, en 2011, el número de personas en la lista de espera creció un 43% y alcanzó los 193.879 pacientes. El Departamento acumuló, entre 2011 y 2014, 38.884 reclamaciones a causa de la tardanza para operarse y en el acceso a las pruebas diagnósticas. El hospital municipal de Badalona y el Parc Taulí de Sabadell acumularon el 25% de las quejas.
Entre los ocho hospitales del Instituto Catalán de la Salud, las reclamaciones por retrasos en operaciones y pruebas diagnósticas suponen el 29% del total. Ruiz acabó 2014 cumpliendo los plazos garantizados, pero a costa de desviar 16.253 enfermos de su hospital de referencia a otros centros.
El nuevo conseller de Salut, Toni Comín, se escuda en que la situación se debe a la falta de presupuesto, que no llega para cumplir con el plan de choque prometido por Junts pel Si. Situación, dice Comín, que solo se puede revertir “con la independencia” de Cataluña. “Cualquier persona comprometida con los derechos sociales debería mirar con mucho interés el escenario de la independencia”, ha dicho, porque permitiría que Cataluña pudiera dar respuesta a los problemas de los ciudadanos.
http://www.pressdigital.es/texto-diario/mostrar/407671/la-delicada-situacion-de-la-sanidad-en-cataluna


información facilitada por

kaosenlared.net 

the cases of Catalonia and Scotland are examples of modern european separatims

The secession conundrum


Teona Surmava - 24 February 2016
policy-network.net  


Uncertainty over future EU membership has recently proved an obstacle for separatist movements within EU member states – but do they present a wider threat to the solidity of the EU?
Separatist movements across the EU have gained momentum in recent years. Despite the many successes of European integration, the bloc still has deep internal divisions. EU solidarity has been tarnished by the growing appeal of nationalistic movements. These manifest themselves both as Eurosceptic movements and as national independence movements.
A crucial element of these centrifugal forces has been the economic crisis in Europe, which has fanned the desire for autonomy in economically viable regions. Separatist movements now strive for autonomy in Italy, Belgium, and France – but most notably in Spain and the United Kingdom.
The cases of Catalonia and Scotland are examples of modern European separatism. Independence movements in these regions regard themselves as European in nature, believing that national independence within EU structures will bring political and economic benefits.
In September 2015, Catalans voted in a decisive regional election billed as a ‘de facto referendum on independence’. Pro-independence parties in Catalonia won an absolute majority in the region’s 135-seat regional parliament. Following the result, Catalan lawmakers voted on a plan to achieve independence from Spain by 2017.
One year before the Catalan regional elections, Scotland held its own independence referendum. More than 2 million voters (55.25 per cent of the total) voted to remain in the United Kingdom. Throughout the referendum, Scots were encouraged to vote against independence by a coalition formed by Britain’s three largest political parties.
Catalonia, as Spain’s most powerful economic region, accounts for a fifth of the country’s economic output. It has long been part of Spain, but the region has deep roots as an independent state from the 11th century and still preserves its language, culture, and autonomous government. As for Scotland, by the 19th century it found itself as one of the most important manufacturing hubs in the British Empire.
“We aspire to become a state and an ally of the states in Europe and in the world” said Raul Romeva, a former Green MEP who led Catalonia’s separatist coalition in the elections of September, 2015. That statement sums up what separatists in Catalonia and Scotland wish to achieve: establishing normal state-relations with other states in Europe, without a larger unit forming an obstacle. “A perfect situation would be like the referendum in Scotland”, said Romeva.
Drawbacks of successful secession
It bears mentioning that among the arguments for Scotland staying in the UK was the uncertainty of it being able to remain in the EU. The logical question arises in the relationship with independence: is the existence of the EU an obstacle for independence movements within EU member states? To analyse possible challenges facing breakaway regions, one must consider the legal and political barriers.
 One of the major obstacles for subnational entities attempting to achieve independence and join the EU as a separate state is the silence of EU treaties on this issue. The EU treaties indeed provide procedures to join or even leave the union, but do not identify steps for how “breakaway” regions can remain in the EU after secession.
Article 49 of the treaty of the European Union clearly states that any European country sharing the core European values envisaged by Article 2 can apply for membership. While under international and EU law regions would lose their EU status after secession and have to re-apply for union membership, proponents of independence seek to challenge this idea. They claim that if the secession is a result of democratic processes, the newly established state has a right to apply for EU membership.  
Another argument by proponents is that, from a pragmatic point of view, existing EU member states should be willing to keep a new state inside the Union if it previously was part of the EU. However, by that same logic, member states should also be willing to prevent internal erosion of the union’s territorial integrity.
Furthermore, since one of the key elements of the EU is enlargement, advocates of independence believe that it would enlarge if separatist regions leave EU and re-apply for membership. However, this actually means the EU would fragment. As the union evokes goal of establishing “an ever-closer union among the peoples of Europe”, fragmentation is at odds with this principle.
From a procedural standpoint, the possibility for a region to rejoin the EU without achieving an agreement with the existing members would conflict with the CJEU’s pronouncement that an accession treaty must be reached between the existing states and the newly joining state.
Notably, proponents of secession argue that instead of using traditional enlargement procedures, Article 48 can be used. A solution offered by Article 48 is the possibility to amend the EU treaties. The treaties could then be translated in a way that allows for a separatist region’s post-independence membership. But in order to launch accession procedures with the EU on its own behalf, the separatist region should be internationally recognised as an independent state at the outset. Therefore, it is problematic whether all member states, and especially those having separatist movements would be willing to do so. This gives significant power to the member states struggling with separatism to derail independence movements within their territory. 
As for the political and economic difficulties, it should be addressed that the denial of EU membership would entail the newly-independent state losing EU benefits, which might create long-term economic challenges. Losing access to the euro currency, membership in the European Economic Area, and the benefits of open borders are serious concerns. As Connor Pfeiffer argues, “the prospect of these difficulties was a potent weapon deployed by the no-vote coalition in Scotland.”
Independence movements threaten the solidity of the EU, which has already been undermined in recent years by the economic crisis, fiscal problems in Greece, and the high possibility that Britain might leave the EU. There are serious concerns that Catalonia’s very public movement towards independence could fan the separatist flames in regions of Italy, Belgium, Germany, and Scotland. Even if Catalonia and Scotland break free, either would be unlikely to gain membership in the European Union or be recognised internationally. Furthermore, their independence could lead to the further fragmentation of the EU through a domino effect.
Teona Surmava is a graduate in Nationalism Studies from the Central European University


© Policy Network

Ciudadanos and PSOE sign deal hoping to win cross-party support

Ciudadanos and PSOE sign deal hoping to win cross-party support

Podemos rejects the agreement: “The Socialists’ choice is incompatible with us”



Pedro Sánchez and Albert Rivera in Congress on Wednesday. /FRANCISCO SECO (AP)
Socialist Party leader Pedro Sánchez and Ciudadanos head Albert Rivera on Wednesday signed a wide-ranging policy agreement that they hope will win the support of other political forces and pave the way for a government led by Sánchez.





“For me it is an honor to be part of this agreement, and I hope to have the honor of sharing it with other political forces”
Pedro Sánchez
Podemos, which has said the pact goes against its party platform on many issues, immediately canceled a meeting it had scheduled with the Socialists (PSOE), Compromís and the United Left (IU) groups scheduled for Wednesday afternoon.
Between now and next week, Sánchez and his PSOE team will try to convince the other parties with whom they have been negotiating to vote in favor of his candidacy.
Iñigo Errejón, the number two official in Podemos, said the “choice of the PSOE is incompatible with us.”



 Ciudadanos changes strategy and agrees to vote for Socialist chief as PM  
 Socialists-Ciudadanos agreement clashes with Podemos’s program  
 PSOE negotiating deal with leftist parties and Ciudadanos in parallel  
“What they have presented today is an agreement written with the Popular Party in mind,” he said.
Rivera, who made a major U-turn earlier Wednesday by announcing that he would be supporting the PSOE leader's bid to become prime minister next week, is particularly hoping to attract the backing of the conservative Popular Party (PP), which won the December 20 elections with 123 seats.
Until now, Rivera had insisted that he would abstain from voting to install Sánchez as prime minister next week and would not support an administration of which he was not directly a part.
But on Wednesday, invoking the cross-party pacts that helped lead Spain from dictatorship to democracy in the late 1970s, Rivera told journalists: “The institutions of the state have to do what is already the norm out in the real world.”
He called on the PP to back the more than 200 measures agreed upon by Ciudadanos and the Socialists, either by directly supporting Sánchez’s bid to become prime minister or at least by abstaining during the vote.
“We cannot do all this alone. We need more parties,” he said in reference to the 130 seats the two parties have between them, which fall short of the majority they need to govern in the 350-seat house.


“The problem is not the numbers, it is the lack of generosity and the willingness to talk”
Albert Rivera
“The problem is not the numbers, but about the lack of generosity and willingness to talk.
The problem is not the numbers, but about the lack of generosity and willingness to talk
““The problem is not the numbers, it is the lack of generosity and the willingness to talk. There is no political will. I invite all parties to join this new transition,” said Rivera.
Earlier, Podemos – the third political force – called the PSOE-Ciudadanos pact “ineffective” and said it went against the party’s own platform on the economy and the push for a referendum on Catalan independence.
“It is part of a spectacle that Spaniards are tired of seeing,” said Sergio Pascual, Podemos organization secretary.
Ciudadanos leader Rivera announced that he did not rule out joining a Socialist-led administration, something that until now he has said he would not do. “The deal includes 80 percent of our program,” he said.
Ciudadanos will send a copy of the program it has hammered out with the Socialists to the PP, although its leader, acting Prime Minister Mariano Rajoy, has repeatedly ruled out supporting Sánchez’s efforts to form a government and will only negotiate with other parties on the basis of a coalition led by the PP.


“Some have described this as little more than a bar-room deal or an advertisement”
Mariano Rajoy
Speaking on Spanish radio on Wednesday morning, Rajoy dismissed the deal between Ciudadanos and the Socialists as a campaign stunt ahead of the general election that will have to take place on June 26 if no government is formed.
“Some have described this as little more than a bar-room deal or an advertisement. I’m not going to discuss such things, and will simply say that it is not enough for an investiture or to form a government,” Rajoy said.
The program inked between Sánchez and Rivera, which covers labor market reform, taxes, regional administration, abortion rights, religious education in schools, and energy policy, will bind the two parties should Sánchez fail in his bid to form a government and a new election has to be held

Politicos y politica

Realmente, tenemos políticos que dan la talla?
La respuesta es No

* Hay politicos elitistas que se dedican a criminalizar según el color de la piel o raza. Donald Tramp está contra la inmigración

* Existen politicos quese defican a expoliar al pueblo para enriquecerse ellos. Mariano Rajoy, o Henry Kisinguer son un ejemplo

* Otra clase de politicos son los que se dedican mentir por naturaleza como ejemplo todos los politicos  que tienen a su cargo las carteras de tributos y economia

EMPIEZAN A DENUNCIAR A LA MAFIA FARMACÉUTICA

REPUTADOS MÉDICOS BRITÁNICOS EMPIEZAN A DENUNCIAR A LA MAFIA FARMACÉUTICA



Varios médicos británicos, entre ellos el que fuera doctor personal de la Reina Isabel II, han iniciado un debate sobre la eficacia de los medicamentos y cuestionan la influencia de las compañías farmacéuticas en el consumo de productos cuya eficacia no está comprobada.
Richard Thompson, expresidente del Real Colegio de Médicos británico y doctor personal de la reina Isabel II durante 21 años, ha reclamado que se realice una consulta pública urgente sobre “la eficacia de los fármacos” y que se revelen los manejos “turbios” de las compañías del sector y ha advertido sobre la influencia excesiva que poseen a la hora de prescribir medicamentos.


Las personas que arremeten contra las farmacéuticas aseguran que muchos medicamentos provocan más perjuicios que beneficios, mientras que las supuestas bondades de algunos medicamentos no están debidamente constatadas.
Y es que el negocio farmacéutico mueve millones de dólares en todo el mundo. Al mismo tiempo, los excesos de medicación y el consumo de múltiples medicamentos cuya eficacia está en duda son algunos de los factores que provocan la muerte de miles de personas.
Al respecto cabe destacar lo que nos dice un médico argentino en el artículo EL COMENTARIO REVELADOR DE UN MÉDICO SOBRE LA PERVERSIÓN DE LA MEDICINA ACTUAL
Entre los médicos que están impulsando el debate sobre el excesivo poder que ejercen las farmacéuticas sobre la actividad médica, se encuentra el cardiólogo Aseem Malhotra, que ha acusado a las empresas farmacéuticas de “jugar con el sistema”, invirtiendo dos veces más en marketing que en investigación.


El Dr. Malhotra sostiene que los medicamentos recetados a menudo hacen más daño que bien, y que los ancianos son el grupo que mayor riesgo corre por culpa de estas prácticas tan extendidas.
“Uno de cada tres ingresos hospitalarios entre los mayores de 75 años en el Reino Unido, son a consecuencia de una reacción adversa a un medicamento”
El Dr. Malhotra, que está poniendo en marcha la campaña de denuncia a título personal, es administrador del Think Tank del campo de la salud King’s Fund, miembro de la Academia de Reales Colegios Médicos y asesor del Foro Nacional de Obesidad del Reino Unido.
Malhotra está recibiendo el respaldo de Sir Richard Thompson, y del profesor John Ashton, presidente de la Facultad de Salud Pública; el psiquiatra Dr. JS Bamrah, presidente de la Asociación Británica de Médicos de Origen Indio; la cardióloga Rita Redberg, editora de la revista médica Archives of Internal Medicine; y el profesor James McCormack, un científico farmacéutico.


Malhotra señala directamente a la sanidad pública británica porque considera que sobremedica a sus pacientes y que los efectos colaterales derivados que provoca esa manera de actuar conducen a “innumerables muertes”.
Además, este cardiólogo indica que existe la sospecha de que ese “exceso de medicina” derive de los “incentivos financieros” vinculados con la prescripción y el aumento de los procedimientos, con lo cual acusa a las farmacéuticas de “jugar con el sistema” y de invertir el doble en propaganda que en investigación.
Malhotra es particularmente crítico con el reciente aumento dramático de la prescripción de estatinas y afirma que los datos completos sobre el poder de las estatinas y sus efectos secundarios no han sido publicados.
En farmacología, se conoce como estatinas a un grupo de fármacos usados para disminuir el colesterol en sus distintas formas, en pacientes que lo tienen elevado (hipercolesterolemia) y que presentan, por tanto, un mayor riesgo de desarrollar ateroesclerosis y de sufrir episodios de patología cardiovascular.
frasco-estatinas
De hecho, cada vez más pruebas sugieren que los beneficios de las estatinas han sido muy exagerados y que sus efectos secundarios han sido ampliamente subestimados.
En las últimas semanas, dos grupos de investigación independientes en Japón y Francia, independientemente uno del otro, han puesto en duda la fiabilidad de muchos de los estudios anteriores patrocinados por la industria farmacéutica, que mostraban los supuestos beneficios de las estatinas.
De hecho, la investigación japonesa fue tan lejos como para sugerir que las estatinas pueden ser una de las causas del creciente número de afectados entre la población, de insuficiencia cardíaca.
Mientras tanto, el reputado cardiólogo francés Dr. Michel De Lorgeril, afirma que todos los estudios publicados después de 2006 no revelan ‘ningún beneficio’ de las estatinas para la prevención de enfermedades cardiovasculares en todos los grupos de pacientes.


Entre otras diversas investigaciones sobre el daño provocado por determinados medicamentos, Malhotra cita una investigación realizada por la revista médica British Medical Journal, que a principios de este mes sugiere que el principal medicamento anticoagulante Rivaroxaban no es tan seguro como sugieren los datos de los ensayos, aunque el regulador sigue apoyando la comercialización del medicamento.
Asimismo denuncia que se produce “una financiación sesgada de la investigación, destinada a favorecer aquellos productos que sean más rentables, y no los que sean más beneficiosos para los pacientes, mediante informaciones sesgadas en revistas médicas”
“De hecho, tal y como dijo John Ioannidis, profesor de medicina y política de salud en la Universidad de Stanford: ‘como mayores sean los intereses financieros en un campo determinado, menos probable es que los resultados de la investigación sean verdad'”
“Todo ello lleva a conflictos de interés de carácter comercial y a una clara incapacidad de los médicos y los pacientes a la hora de entender las estadísticas de salud y el riesgo de los productos farmacéuticos”
“Todo lo anterior están contribuyendo a una epidemia de médicos y pacientes mal informados en el Reino Unido y en todas partes”
“Pero lo más preocupante de todo, es que esta situación desesperada está costando decenas de miles de vidas en todo el mundo”
“Además, el problema con la polifarmacia (tomar más de un medicamento a la vez), es que como más medicamentos se toman, más probable es que el paciente experimente efectos secundarios que luego son mal interpretados por un médico o enfermera como un síntoma de enfermedad que necesita tratamiento con medicamentos adicionales”


Hace unos meses, el director médico del NHS (Servicio Nacional de Salud de Inglaterra), Sir Bruce Keogh, admitió que uno de cada siete tratamientos del NHS, incluyendo operaciones, eran innecesarias y que no deberían haberse llevado a cabo en los pacientes.
Y en los EE.UU., se estima que un tercio de todas las actividades de cuidado de la salud no aportan ningún beneficio a los pacientes.
Esto está respaldado además por una observación hecha por la ex editora de la revista New England Journal of Medicine, la Dra. Marcia Angell.
En una conferencia pronunciada en la Universidad de Montana, en 2009, reveló que de los 667 nuevos medicamentos aprobados por la FDA entre 2000 y 2007, sólo el 11% eran considerados innovadores o eran una mejora de algún medicamentos ya existente.
Sin embargo, tres cuartas partes eran esencialmente sólo copias de los antiguos medicamentos, que eran recomercializados para ganar aún más dinero con ellos.
“Teniendo en cuenta el hecho de que la responsabilidad primaria de las compañías farmacéuticas es proporcionar beneficios a los accionistas, en lugar de preocuparse por la salud del paciente, eso no debería sorprender a nadie”, afirma el Dr. Malhotra.
Pero aparte del despilfarro financiero colosal que resulta de que las empresas lancen al mercado un mismo medicamento dos veces, y por lo tanto gasten el doble en marketing que lo que invierten en investigación y desarrollo, lo peor es el daño considerable sobre los pacientes y el público.


La Administración de Medicamentos y Alimentos de EEUU (FDA) informa que los efectos adversos de los medicamentos prescritos se han más que triplicado en la última década en los Estados Unidos, lo que ha dado lugar a más de 123.000 muertes en 2014 y 800.000 resultados de pacientes sufriendo efectos graves, incluyendo hospitalizaciones y discapacidades que amenazan su vida…aunque muchos expertos afirman que estos datos subestiman la verdad, que es mucho peor.
Uno de los expertos que lleva denunciando desde hace tiempo los peligros de la medicación moderna es Peter Gotzsche, profesor de diseño y análisis de la investigación en la Universidad de Copenhague.


Gotzsche estima que los medicamentos recetados son la tercera causa más común de muerte después de las enfermedades cardíacas y el cáncer.
En particular, está profundamente preocupado por el impacto de las drogas psiquiátricas como los antidepresivos y los fármacos contra la demencia.
Escribiendo en la revista British Medical Journal, ha calculado que son responsables de más de medio millón de muertes en las personas mayores de 65 años en la Unión Europea y en los Estados Unidos.
De hecho, debido a estas actitudes y manejos poco claros, entre 2007 y 2012 casi todas las farmacéuticas que se encuentran entre las 10 más importantes del mundo pagaron multas considerables por delitos como la tergiversación de resultados de investigación, el ocultamiento de información sobre los daños de sus productos y la comercialización ilegal de fármacos.


Y así lo empiezan a denunciar médicos reputados en países como el Reino Unido, donde empiezan a revelar que el sistema médico actual está controlado completamente por los intereses de la industria farmacéutica.
Sin embargo, aún hay gran cantidad de gente que se niega a ver esta evidencia y en muchos países, como por ejemplo España, los médicos apenas se atreven a denunciar las prácticas criminales de la industria farmacéutica, que han secuestrado por completo la práctica de la medicina, corrompiéndola y pervirtiéndola hasta convertirla en un mero negocio, infinitamente más preocupado de ganar ingentes cantidades de dinero, que de preocuparse de la salud de los pacientes.

Fuente: http://www.dailymail.co.uk/health/article-3460321/How-Big-Pharma-greed-killing-tens-thousands-world-Patients-medicated-given-profitable-drugs-little-proven-benefits-leading-doctors-warn.html
https://actualidad.rt.com/actualidad/200446-negocio-farmaceutico-muerte-miles-pacientes